BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260516T063440
CREATED:20230202T110957Z
LAST-MODIFIED:20230202T110957Z
UID:36469-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotides for CNS Summit
DESCRIPTION:With approvals in siRNA technology\, more ASOs hurtling towards human trials in neurology\, and exciting headlines in Alzheimer’s and ALS\, the draw of CNS targets for oligonucleotides has never been greater. Massive investments and growing pipelines in pharma and biotech alike are working to make these life-changing therapies a reality for previously undruggable targets. \nJoin 100+ experts and dedicated scientists at the 3rd Oligonucleotides for CNS\, the definitive industry forum bringing together leaders to problem-solve\, explore invention\, and inspire the creation of next-generation oligonucleotide drugs for neurological disorders. Gather with specialists from Biogen\, Ionis\, Genentech\, Eli Lilly\, Servier\, and Stoke\, spanning disciplines of biology\, chemistry\, toxicology\, and clinical innovation. \nTackle genomic target validation\, backbone chemistry\, effective intracellular delivery\, and potency\, increased stability for reduced dosing\, novel cerebral organoids\, CNS device delivery\, and CSF oligo distribution to uncover the best approaches for each phase in your pipeline. Take away invaluable lessons that will translate directly into optimizing your oligonucleotide pipeline for the CNS. \nTo know more visit: https://ter.li/i5y7zn
URL:https://www.pharmajournalist.com/event/3rd-oligonucleotides-for-cns-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260516T063440
CREATED:20230207T095425Z
LAST-MODIFIED:20230207T095425Z
UID:36545-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders Summit Europe
DESCRIPTION:Returning as the pinnacle event in the industry\, the 4th Annual Gene Therapy for Neurological Disorders Summit Europe (6-8 June 2023\, Amsterdam) enables you to bring your gene therapy to patients in Europe. This year’s content takes a greater focus on: \n\nInnovation in preclinical models and vector technology\nShowcasing novel approaches to improve delivery in a safe manner\nOptimizing administration route to reduce the patient\nUnderstanding what needs to be done to crack the European market\n\nDownload the agenda to find out more – https://ter.li/1mmd4t \nCovering both neurodevelopmental and neurodegenerative disorders\, join 80+ of your peers in Amsterdam this June. We’ll be welcoming those leading biopharma and academia\, working in preclinical\, clinical and market access to help get safer\, more efficacious gene therapies for neurological disorders to market in Europe. \nAs the gene therapy community gets a second wind and as the clinical promise in neurology begins to be realised\, now is the time to get your hands on the latest innovations in this field to bring safe\, efficacious and commercially successful products to market in Europe.  \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/azxig5
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders-summit-europe/
LOCATION:Room Mate Aitana\, IJdok 6\, 1013 MM\, Amsterdam\, 1013 MM\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR